Literature DB >> 21533530

Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

Julie Johnson1, Sue Healey, Kum Kum Khanna, Georgia Chenevix-Trench.   

Abstract

Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in homologous recombination (HR) repair of DNA double-strand breaks (DSBs); it also interacts directly with p53. Deleterious mutations have been found in one RAD51 paralog, RAD51C (RAD51L2), in non-BRCA1/2 breast and ovarian cancer families, which suggests that all five paralogs are strong candidate breast cancer susceptibility genes. A genome-wide association study (GWAS) has already identified a single nucleotide polymorphism (SNP) deep within intron 10 of RAD51L1 as a risk locus for breast cancer. Based on its biological functions and association with RAD51C, there is reason to suggest that RAD51L1 (RAD51B/REC2) may also contain high risk mutations in the gene that give rise to multiple-case breast cancer families. In order to investigate this hypothesis, we have used high resolution melt (HRM) analysis to screen RAD51L1 for germline mutations in 188 non-BRCA1/2 multiple-case breast cancer families and 190 controls. We identified a total of seven variants: one synonymous, three intronic, and three previously identified SNPs, but no truncating or nonsense changes. Therefore, our results suggest that RAD51L1 is unlikely to represent a high-penetrance breast cancer susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533530     DOI: 10.1007/s10549-011-1539-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Analyzing 395,793 samples shows significant association between rs999737 polymorphism and breast cancer.

Authors:  Haiying Dong; Zhiying Gao; Chengchong Li; Junping Wang; Ming Jin; Hua Rong; Yingcai Niu; Jicheng Liu
Journal:  Tumour Biol       Date:  2014-04-12

2.  Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damage.

Authors:  Na Wei; Yi Shi; Lan N Truong; Kathleen M Fisch; Tao Xu; Elisabeth Gardiner; Guangsen Fu; Yun-Shiuan Olivia Hsu; Shuji Kishi; Andrew I Su; Xiaohua Wu; Xiang-Lei Yang
Journal:  Mol Cell       Date:  2014-10-02       Impact factor: 17.970

3.  TBX15 rs98422, DNM3 rs1011731, RAD51B rs8017304, and rs2588809 Gene Polymorphisms and Associations With Pituitary Adenoma.

Authors:  Gabija JuknytĖ; Inga LaurinaitytĖ; Alvita VilkeviČiŪtĖ; Greta GedvilaitĖ; Brigita GlebauskienĖ; Loresa KriauČiŪnienĖ; Rasa LiutkeviČienĖ
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Germline mutation in the RAD51B gene confers predisposition to breast cancer.

Authors:  Lisa Golmard; Virginie Caux-Moncoutier; Grégoire Davy; Essam Al Ageeli; Brigitte Poirot; Carole Tirapo; Dorothée Michaux; Catherine Barbaroux; Catherine Dubois d'Enghien; André Nicolas; Laurent Castéra; Xavier Sastre-Garau; Marc-Henri Stern; Claude Houdayer; Dominique Stoppa-Lyonnet
Journal:  BMC Cancer       Date:  2013-10-19       Impact factor: 4.430

5.  RAD51B in Familial Breast Cancer.

Authors:  Liisa M Pelttari; Sofia Khan; Mikko Vuorela; Johanna I Kiiski; Sara Vilske; Viivi Nevanlinna; Salla Ranta; Johanna Schleutker; Robert Winqvist; Anne Kallioniemi; Thilo Dörk; Natalia V Bogdanova; Jonine Figueroa; Paul D P Pharoah; Marjanka K Schmidt; Alison M Dunning; Montserrat García-Closas; Manjeet K Bolla; Joe Dennis; Kyriaki Michailidou; Qin Wang; John L Hopper; Melissa C Southey; Efraim H Rosenberg; Peter A Fasching; Matthias W Beckmann; Julian Peto; Isabel Dos-Santos-Silva; Elinor J Sawyer; Ian Tomlinson; Barbara Burwinkel; Harald Surowy; Pascal Guénel; Thérèse Truong; Stig E Bojesen; Børge G Nordestgaard; Javier Benitez; Anna González-Neira; Susan L Neuhausen; Hoda Anton-Culver; Hermann Brenner; Volker Arndt; Alfons Meindl; Rita K Schmutzler; Hiltrud Brauch; Thomas Brüning; Annika Lindblom; Sara Margolin; Arto Mannermaa; Jaana M Hartikainen; Georgia Chenevix-Trench; Laurien Van Dyck; Hilde Janssen; Jenny Chang-Claude; Anja Rudolph; Paolo Radice; Paolo Peterlongo; Emily Hallberg; Janet E Olson; Graham G Giles; Roger L Milne; Christopher A Haiman; Fredrick Schumacher; Jacques Simard; Martine Dumont; Vessela Kristensen; Anne-Lise Borresen-Dale; Wei Zheng; Alicia Beeghly-Fadiel; Mervi Grip; Irene L Andrulis; Gord Glendon; Peter Devilee; Caroline Seynaeve; Maartje J Hooning; Margriet Collée; Angela Cox; Simon S Cross; Mitul Shah; Robert N Luben; Ute Hamann; Diana Torres; Anna Jakubowska; Jan Lubinski; Fergus J Couch; Drakoulis Yannoukakos; Nick Orr; Anthony Swerdlow; Hatef Darabi; Jingmei Li; Kamila Czene; Per Hall; Douglas F Easton; Johanna Mattson; Carl Blomqvist; Kristiina Aittomäki; Heli Nevanlinna
Journal:  PLoS One       Date:  2016-05-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.